ATP-binding cassette (ABC) transporters are a large and diverse group of transmembrane proteins that use the energy ATP hydrolysis to transport a wide variety of substrates across cellular membranes. These substrates include lipids, bile salts, amino acids, carbohydrates, vitamins, hormones, drugs, and metabolites. ABC transporters are crucial for many physiological processes, such as lipid transport in the liver, drug excretion in the kidneys, and antigen presentation in the immune system. Their role in effluxing xenobiotics and drugs out of cells also makes them key players in multidrug resistance, particularly in cancer cells. The activity of ABC transporters is tightly regulated by cellular signaling pathways, ensuring that substrate transport is coordinated with the cell's metabolic needs and environmental conditions.
Targeting ATP-binding cassette (ABC) transporters for disruption or inhibition has become an important strategy in various research and application fields. In medical research, inhibiting specific ABC transporters, especially those involved in drug resistance, is a strategy to enhance the efficacy of agents in cancer therapy. Pharmacological inhibitors of ABC transporters can be used to increase the bioavailability of drugs by their efflux from target cells. Researchers also target ABC transporters to study their role in physiological processes and disease states, employing a range of inhibitors that can specifically or broadly target these transporters. However, the challenge in targeting ABC transporters lies in their broad substrate specificity and the potential for unintended effects on normal physiological functions, necessitating the development of highly selective and efficient inhibitors.
Items 1 to 10 of 12 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | ¥699.00 ¥1015.00 ¥3373.00 ¥5359.00 ¥11451.00 ¥23681.00 | 69 | |
环孢素 A 是一种免疫抑制剂,通过与 P 糖蛋白结合抑制 ATP 结合盒(ABC)转运体,阻止其药物外流活性。 | ||||||
Elacridar | 143664-11-3 | sc-207613A sc-207613 sc-207613B sc-207613C sc-207613D | 5 mg 10 mg 50 mg 100 mg 1 g | ¥1083.00 ¥1252.00 ¥4547.00 ¥5810.00 ¥28826.00 | 19 | |
Elacridar 可通过与 P-glycoprotein 结合抑制 ATP 结合盒(ABC)转运体,阻止药物外流,从而促进药物向靶组织的输送。 | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | ¥1218.00 ¥2256.00 ¥4806.00 | 9 | |
通过改变膜流动性和破坏其转运活性来干扰 ATP 结合盒 (ABC) 转运体的功能,从而可能导致胆汁淤积。 | ||||||
Bosentan | 147536-97-8 | sc-210957 | 10 mg | ¥2155.00 | 3 | |
通过直接与 ATP 结合盒 (ABC) 转运体相互作用抑制该转运体,导致胆汁酸转运减少和潜在的肝毒性。 | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | ¥1072.00 ¥3633.00 ¥7480.00 ¥16224.00 | 6 | |
作为一种 ATP 结合盒(ABC)转运体抑制剂,可与转运体结合并破坏其功能,从而可能导致药物引起的肝损伤。 | ||||||
Fluvastatin, Sodium Salt | 93957-55-2 | sc-202613 sc-202613A sc-202613B | 25 mg 50 mg 100 mg | ¥1027.00 ¥1523.00 ¥2719.00 | 1 | |
可能会通过改变膜组成和影响转运体功能来抑制 ATP 结合盒 (ABC) 转运体,从而可能导致肝胆不良反应。 | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | ¥699.00 ¥2933.00 | 21 | |
通过在分子水平上干扰 ATP 结合盒 (ABC) 转运体的功能来抑制该转运体,从而导致胆汁淤积和胆汁酸分泌受损。 | ||||||
Erythromycin | 114-07-8 | sc-204742 sc-204742A sc-204742B sc-204742C | 5 g 25 g 100 g 1 kg | ¥632.00 ¥2708.00 ¥9195.00 ¥14723.00 | 4 | |
可抑制 ATP 结合盒 (ABC) 转运体,改变其功能,可能导致胆汁酸蓄积和肝中毒。 | ||||||
Naringenin | 480-41-1 | sc-219338 | 25 g | ¥2764.00 | 11 | |
通过调节细胞途径或直接与转运体相互作用,作用于 ATP 结合盒(ABC)转运体,从而可能影响胆汁酸的转运。 | ||||||
Tolvaptan | 150683-30-0 | sc-364638 sc-364638A | 10 mg 50 mg | ¥1376.00 ¥6905.00 | ||
可能会通过影响细胞过程来影响 ATP 结合盒 (ABC) 转运体的功能,从而可能导致胆汁酸分泌受损。 |